Preoperative CRP(-)/CEA(-)/CA19-9(-)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence

Mitsunori Ushigome; Hideaki Shimada; Tomoaki Kaneko; Yasuyuki Miura; Yasuo Nagashima; Takayuki Suzuki; Satoru Kagami; Akiharu Kurihara; Kimihiko Funahashi

doi:10.23922/jarc.2022-010

Preoperative CRP(-)/CEA(-)/CA19-9(-)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence

J Anus Rectum Colon. 2022 Oct 27;6(4):264-273. doi: 10.23922/jarc.2022-010. eCollection 2022.

Authors

Mitsunori Ushigome¹, Hideaki Shimada¹, Tomoaki Kaneko¹, Yasuyuki Miura¹, Yasuo Nagashima¹, Takayuki Suzuki¹, Satoru Kagami¹, Akiharu Kurihara¹, Kimihiko Funahashi¹

Affiliation

¹ Department of Surgery, Toho University School of Medicine, Tokyo, Japan.

Abstract

Objectives: We evaluated the prognostic impact of a novel C-reactive protein (CRP) cut-off value (0.6 mg/dl) and carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9) in stage II/III colorectal cancer.

Methods: Four hundred ninety-eight patients with stage II (n = 275) or stage III (n = 223) colorectal cancer, surgically treated between January 2010 and December 2016, were analyzed. The optimal CRP cut-off value was fixed at 0.6 mg/dl to predict recurrence based on the receiver operating characteristic curve. Prognostic factors, including CRP/CEA/CA19-9 status, for relapse-free survival (RFS) were evaluated by multivariate analysis.

Results: Recurrent rates were 15% and 32% in stages II and III, respectively. In stage II, CRP, CEA, and CA19-9 were not significant prognostic factors for RFS. In stage III, the RFS of the low CRP group was significantly better than that of the high CRP group (p = 0.002). In stage III, the RFS of CRP(-)/CEA(-) or CRP(-)/CA19-9(-) was significantly better than the other group, as opposed to the RFS of the CEA(-)/CA19-9(-) group that was not. The CRP(-)/CEA(-)/CA19-9(-) group recurrence rate in stage III was significantly better than the CRP(+)/CEA(-)/CA19-9(-) group (20% vs. 50%, p = 0.006). Multivariate analysis revealed that CRP(-)/CEA(-)/CA19-9(-) (p = 0.04) and non-T4 (p < 0.001) were good independent prognostic factors in stage III. The CRP(-)/CEA(-)/CA19-9(-)/non-T4 group recurrence rate in stage III was 11% (8 out of 73).

Conclusions: In stage III, the CRP(-)/CEA(-)/CA19-9(-)/non-T4 group is favorable risk for recurrence.

Keywords: CA19-9; CEA; CRP; colorectal cancer; relapse-free survival.